AZ-UNIVERSAL-ELECTRONICS
22.12.2022 12:06:42 CET | Business Wire | Press release
Universal Electronics Inc. (NASDAQ: UEIC), the worldwide leader in universal control technology for entertainment and smart home devices today announced that it has been named a CES® 2023 Innovation Awards Honoree for its UEI Eterna remote control. This year’s CES Innovation Awards program received a record-high number of over 2100 submissions. The announcement was made ahead of CES 2023, the world’s most influential technology event, happening Jan. 5-8 in Las Vegas, NV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005096/en/
UEI's Eterna Remote Receives the CES 2023 Innovation Award (Graphic: Business Wire)
Maximum performance with minimum battery waste
Targeting TV service providers that want to minimize their carbon footprint and battery waste without compromising on the consumer experience, UEI has designed and developed its most advanced and sustainable voice remote-control platform ever.
The UEI Eterna family of products are built with UEI’s new Xtreme Low-Power Bluetooth LE silicon making them 2.5 times more powerful and up to 10 times more efficient than the previous generation of voice remote controls. In combination with a revolutionary high-density photovoltaic panel that harvests three times more energy than traditional panels, it can self-power despite intense usage or in low light conditions.
For better accessibility in the dark, the UEI Eterna line supports Ambient-Aware backlighting. The backlight activates when there is insufficient lighting in the room. This further reduces power consumption to a bare minimum. UEI Eterna is built with recycled and recyclable materials and packaged free of single-use plastics (SUP). To facilitate refurbishment and recycling programs, the products are specifically designed for easy disassembly which helps to minimize waste and maximize the re-use of field returned units.
“With sustainability as a driving force for product innovation and design at UEI, we are delighted that our UEI Eterna product received this award,” said Menno Koopmans, SVP of Global Sales and Marketing. “The UEI Eterna remote is the first of its kind that delivers on our customers’ sustainability goals without having to compromise on user experience or product features. This innovation is a clear milestone on our journey towards a battery-less world.”
The UEI Eterna and UEI Eterna XLR also feature a unique Interactive Light Bar that communicates its status in real-time with the end user using distinct and recognizable light patterns.
The product line comes with a unique pre-integrated support system that enhances its sustainability performance as it minimizes customer service calls or related truck rolls:
- Powered by QuickSet® Cloud, it supports UEI’s unique and widely adopted automated discovery and set-up capability to pair the set-top-box remote with the customer’s TV, soundbar or audio system. In 2022 alone, QuickSet is estimated to have saved UEI’s existing pay TV customers over 4 million man-hours of programming time.
- It is supported by UEI’s Virtual Agent that provides self-help capabilities during installation, feature discovery and troubleshooting, and is available on both the TV screen and the mobile device.
- It comes with the turnkey white label My Nevo Companion App to enable the setup and support via a mobile device, customize the user preferences, and optimize power management.
- UEI’s new plug-and-play SDK facilitates easy and trouble-free integration with Android TV set-top boxes.
The UEI Eterna family of products is developed for Android TV and RDK operating systems and is scheduled to be available by the end of the first quarter of 2023.
To schedule a press tour or demo please visit here, or come by our booth #52014 at the Venetian Expo at CES taking place in Las Vegas on January 5-8.
About the CES Innovations Award
The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 28 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetics and design.
About Universal Electronics
Universal Electronics Inc. (NASDAQ:UEIC), Universal Electronics Inc. (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices; designs, develops, manufactures, ships and supports hardware and software control and sensor technology solutions. UEI partners with many Fortune 500 customers, including Comcast, Vivint Smart Home, Samsung, LG, Sony, and Daikin to serve video, telecommunications, security service providers, television, smart home, and HVAC system manufacturers. For over 35 years, UEI has been pioneering breakthrough innovations such as voice control and QuickSet cloud, the world’s leading platform for automated set-up and control of devices in the home. For more information visit www.uei.com
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery, technical performance, and market acceptance of products and technologies identified in this release; the purchasing by UEI customers of the UEI ETERNA products identified in this release in the quantities anticipated by management; the adoption of the energy harvesting and low power technologies identified in this release by UEI customers, the continued penetration and growth of UEI low power, energy harvesting, and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005096/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom